Lakefront Biotherapeutics (GLPG.AS) Stock Analysis & Winston Score

Galapagos is a Belgian biotechnology company that discovers and develops new medicines. It focuses on diseases where patients have few good treatment options, including cancers of the blood and inflammatory conditions. The company is best known for its drug research programs in Europe and has a history of partnering with large pharmaceutical companies to help fund and commercialize its discoveries.

Galapagos earns money through a mix of collaboration deals, milestone payments, and royalties from partners, rather than selling medicines directly to patients at large scale. It operates primarily in Europe, with its main research hub in Belgium and the Netherlands, and holds a significant cash reserve that gives it financial stability. The key growth driver is successfully advancing its pipeline of cancer treatments through clinical trials, but the main risk is that drug development is expensive and uncertain — most experimental medicines fail before reaching patients.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-91.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+109.4% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$417M/ year

↑ Rising (+24% vs prior year)

37.5% of revenue

2.1x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

32.4%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~3 months

$67M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Lakefront Biotherapeutics is putting 37% of revenue into R&D and that number is rising. That's 2.1x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.6% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 65.5M (2021) → 65.9M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

26.0%

Modest — 26.0% gross margin

Operating Margin

-999.6%

Losing money on operations — -999.6%

ROCE

-2.0%

Weak — -2.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+262.2%

Fast-growing sales (262.2% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

-60%

Weak — only -60% of profit becomes cash

FCF Margin

-28.9%

Burning cash (-28.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

23.07x

Comfortably covers interest (23.1x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

3.6x

Attractive valuation — P/E 3.6

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial